Aurinia Pharmaceuticals to Release Fourth Quarter and Year End 2020 Financial Results on February 24, 2021

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the "Company") today announced that it will release its fourth quarter and year end 2020 financial results on Wednesday, February 24, 2021, after the markets close. Aurinia's management team will host a conference call to discuss the Company's financial results and to provide a general business update.

The conference call and webcast is scheduled for February 24, 2021 at 4:30pm ET. In order to participate in the conference call, please dial +1-877-407-9170 (Toll-free U.S. & Canada). An audio webcast can be accessed under "News/Events" through the "Investors" section of the Aurinia corporate website at www.auriniapharma.com . A replay of the webcast will be available on Aurinia's website.

ABOUT AURINIA

Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. The Company has introduced LUPKYNIS™ (voclosporin), the first FDA-approved oral therapy dedicated for the treatment of adult patients with active lupus nephritis (LN). The Company's head office is in Victoria, British Columbia, its U.S. commercial hub is in Rockville, Maryland, and the Company focuses its development efforts globally.

Investor Contact:  
Glenn Schulman, PharmD, MPH
SVP, Corporate Communications & IR
gschulman@auriniapharma.com

News Provided by Business Wire via QuoteMedia

The Conversation (0)

AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS

Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 versus comparable periods in 2023.

"Robust growth in sales and earnings throughout 2024 reflects the momentum of our business. With strong performance globally, we are investing heavily in our rapidly advancing pipeline to deliver innovative therapies across our four therapeutic areas," said Robert A. Bradway , chairman and chief executive officer.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS

Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 versus comparable periods in 2023.

"Robust growth in sales and earnings throughout 2024 reflects the momentum of our business. With strong performance globally, we are investing heavily in our rapidly advancing pipeline to deliver innovative therapies across our four therapeutic areas," said Robert A. Bradway , chairman and chief executive officer.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
CWENCH Hydration Strengthens its Retail Footprint in Western Canada with Placement in 75 Locations of London Drugs

CWENCH Hydration Strengthens its Retail Footprint in Western Canada with Placement in 75 Locations of London Drugs

Founded in 1945, London Drugs is a major retail pharmacy chain with 79 locations in the Western Canadian provinces. Starting in January, three flavours of CWENCH Hydration™ will be available in 75 locations of London Drugs, as well as through its online store.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Cardiol Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

Cardiol Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, is pleased to announce that it will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 11, 2025, at 4:00 p.m. EST.

A live webcast of the presentation will be available under "Events & Presentations" in the Investors section of the Cardiol website (www.cardiolrx.com/investors/events-presentations/).

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

AMGEN ANNOUNCES WEBCAST OF 2024 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS

Amgen (NASDAQ:AMGN) today announced that it will report its fourth quarter and full year 2024 financial results on Tuesday, February 4, 2025 after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 4:30 p.m. ET . Participating in the call from Amgen will be Robert A. Bradway chairman and chief executive officer, and other members of Amgen's senior management team.

Live audio of the conference call will be simultaneously broadcast over the internet and will be available to members of the news media, investors and the general public.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

AMGEN ANNOUNCES WEBCAST OF 2024 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS

Amgen (NASDAQ:AMGN) today announced that it will report its fourth quarter and full year 2024 financial results on Tuesday, February 4, 2025 after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 4:30 p.m. ET . Participating in the call from Amgen will be Robert A. Bradway chairman and chief executive officer, and other members of Amgen's senior management team.

Live audio of the conference call will be simultaneously broadcast over the internet and will be available to members of the news media, investors and the general public.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×